Vicore Pharma Completes ASPIRE Trial Enrollment in IPF
Stockholm, Sweden – April 22, 2026 In a significant advancement for respiratory therapeutics, Vicore Pharma has announced the successful...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Stockholm, Sweden – April 22, 2026 In a significant advancement for respiratory therapeutics, Vicore Pharma has announced the successful...
Stockholm, Sweden, December 19, 2025 — Vicore Pharma Holding AB (publ) announced that it will move from the Nasdaq...
